Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666817 | 1.00 | MME (0.50) | MME | |
| SCHEMBL21794915 | 1.00 | MME (0.50) | MME | |
| Water SCHEMBL29655496 | 0.99 | MME (0.49) | MME | |
| SCHEMBL29577210 | 0.97 | MME (0.47) | MME | |
| SCHEMBL7277013 | 0.95 | CTSC (0.47) | MME | |
| SCHEMBL9667576 | 0.95 | CTSC (0.47) | MME | |
| SCHEMBL9672005 | 0.95 | CTSC (0.47) | MME | |
| SCHEMBL9666897 | 0.95 | CTSC (0.47) | MME | |
| SCHEMBL3881794 | 0.95 | CTSC (0.47) | MME | |
| SCHEMBL9667566 | 0.95 | CTSC (0.47) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| EP-2124880-B1 | FLUORESCENT NANOPARTICLES | EXCHANGE IMAGING TECH GMBH (DE) | 2018-03-21 | — | — | EP | claimed |
| EP-1787659-B1 | Fluorescent nanoparticles | EXCHANGE IMAGING TECH GMBH (DE) | 2017-03-22 | — | — | EP | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2007057182-A2 | FLUORESCENT NANOPARTICLES | SIGNALOMICS GMBH (AT) | 2007-05-24 | — | — | WO | claimed |
| EP-1787659-A1 | Fluorescent nanoparticles | Signalomics GmbH (DE) | 2007-05-23 | — | — | EP | claimed |
| WO-2007001438-A2 | FUNCTIONALIZED FLUORESCENT NANOCRYSTALS, AND METHODS FOR THEIR PREPARATION AND USE | MOLECULAR PROBES, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060216759-A1 | Functionalized fluorescent nanocrystals, and methods for their preparation and use | Life Technologies Corporation | 2006-09-28 | — | — | US | claimed |
| EP-0291626-A2 | Process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-11-23 | — | — | EP | claimed |
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | claimed |
| US-4560515-A | NON-SYMMETRICAL KETENE REACTED WITH A-HYDROXYNITRILE; TERTUARY AMINE CATALYST | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | claimed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| EP-0109681-A2 | process for the preparation of optically-active cyanomethyl esters | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | MME 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.